 |
인쇄하기
취소
|
Boryung wins patent nullification trial over oxaliplatin
Boryung Pharm won the right to market a liquid form of oxaliplatin for cancer.
The company announced on June 4 that it secured the right to sell a generic version of Sanofi-Aventis’s Eloxatin on the Korean market after the Patent Court of Korea said that Eloxatin lacks any novelty in its patent, following the same ruling by a patent trial board.
The board said in its ruling that Eloxatin ...
The company announced on June 4 that it secured the right to sell a generic version of Sanofi-Aventis’s Eloxatin on the Korean market after the Patent Court of Korea said that Eloxatin lacks any novelty in its patent, following the same ruling by a patent trial board.
The board said in its ruling that Eloxatin ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.